Novo Nordisk goes “on the offensive” following Trump deal that also included rival Eli Lilly, putting an exclamation point on rapidly declining GLP-1 drug prices. Experts say the unusual situation makes it hard to predict what’s next.
As GLP-1s Hit Bargain Bin Prices, What’s the Future of the Obesity Market?